- Home
- EVCM vs KNSA Comparison
EVCM vs KNSA Comparison
Compare EVCM & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVCM
- KNSA
- Stock Information
- Founded
- EVCM 2006
- KNSA 2015
- Country
- EVCM United States
- KNSA United Kingdom
- Employees
- EVCM N/A
- KNSA N/A
- Industry
- EVCM EDP Services
- KNSA Biotechnology: Pharmaceutical Preparations
- Sector
- EVCM Technology
- KNSA Health Care
- Exchange
- EVCM Nasdaq
- KNSA Nasdaq
- Market Cap
- EVCM 1.7B
- KNSA 1.9B
- IPO Year
- EVCM 2021
- KNSA 2018
- Fundamental
- Price
- EVCM $10.02
- KNSA $33.07
- Analyst Decision
- EVCM Buy
- KNSA Strong Buy
- Analyst Count
- EVCM 12
- KNSA 6
- Target Price
- EVCM $11.67
- KNSA $40.83
- AVG Volume (30 Days)
- EVCM 188.4K
- KNSA 670.7K
- Earning Date
- EVCM 08-06-2025
- KNSA 07-29-2025
- Dividend Yield
- EVCM N/A
- KNSA N/A
- EPS Growth
- EVCM N/A
- KNSA N/A
- EPS
- EVCM N/A
- KNSA 0.07
- Revenue
- EVCM $703,186,000.00
- KNSA $529,332,000.00
- Revenue This Year
- EVCM N/A
- KNSA $37.21
- Revenue Next Year
- EVCM $6.31
- KNSA $6.10
- P/E Ratio
- EVCM N/A
- KNSA $500.64
- Revenue Growth
- EVCM 7.84
- KNSA 56.18
- 52 Week Low
- EVCM $8.10
- KNSA $17.82
- 52 Week High
- EVCM $12.34
- KNSA $33.98
- Technical
- Relative Strength Index (RSI)
- EVCM 38.32
- KNSA 71.07
- Support Level
- EVCM $9.95
- KNSA $26.27
- Resistance Level
- EVCM $11.70
- KNSA $31.92
- Average True Range (ATR)
- EVCM 0.45
- KNSA 1.17
- MACD
- EVCM -0.18
- KNSA 0.57
- Stochastic Oscillator
- EVCM 3.61
- KNSA 88.20
About EVCM EverCommerce Inc.
EverCommerce Inc provides tailored Software-as-a-Service solutions for service-based small- and medium-sized businesses (SMBs) in-home services, health services, and fitness & wellness. With a platform serving approximately 708,000 customers across three core verticals, including numerous micro-verticals, their solutions address diverse needs within these sectors. Revenue is primarily generated from the United States. Operating in a single segment, their vertically-tailored SaaS offerings cater to SMBs' specialized demands, enabling them to automate processes, generate business, and enhance customer loyalty. The majority of customers contribute modest revenue, with a small percentage contributing higher amounts.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.